Temporary Portocaval Shunt in Living Donor Liver Transplantation
In living donor liver transplantation (LDLT), a temporary portocaval shunt (TPCS) should be used selectively based on intraoperative portal vein pressure >20 mmHg or in high-risk situations including severe perihepatic adhesions, difficult hepatectomy, or small-for-size grafts (GRWR <0.8%). The technique provides superior hemodynamic stability, reduces blood loss, and shortens operative time 1.
When to Use TPCS
Primary Indications:
Portal vein pressure >20 mmHg measured at laparotomy 2
High-risk hepatectomy scenarios:
Small-for-size grafts (GRWR 0.6-0.8%) to prevent small-for-size syndrome 2
High MELD score patients (>20) who benefit most from hemodynamic stabilization 3
Predictive Value:
The TPCS flow during the anhepatic phase correlates significantly with post-reperfusion portal vein flow (R² = 0.3, P < 0.001), allowing identification of patients at risk for excessive portal hyperflow before graft reperfusion 5.
Technical Approach
Standard Technique:
Timing: Create the shunt after early portal vein section, before liver mobilization, to achieve hepatectomy of a totally devascularized liver 6
Direct portocaval shunt options:
- End-to-side anastomosis between portal vein and IVC
- Right-branch portocaval shunt
- Iliac venous conduit interposition when direct access is difficult (obese patients, hypertrophic segment I, or late retransplantation) 4
Indirect shunt alternatives:
Target Hemodynamics:
- Regulate portal vein pressure to <20 mmHg post-shunt creation 2
- Monitor shunt flow to predict post-reperfusion portal flow 5
Clinical Benefits (Evidence-Based)
Intraoperative Advantages:
The 2024 randomized controlled trial demonstrated that TPCS provides 1:
- Significantly reduced blood loss (median, P = 0.004)
- Reduced blood product transfusions (P < 0.05)
- Superior hemodynamic stability during anhepatic phase (P < 0.0001)
- Less vasopressor requirement
- Better renal function with higher intraoperative urine output (P = 0.002)
- Shorter operative time (529 vs 607 minutes, P < 0.0001)
- Fewer IVC injuries (3.3% vs 26.7%, P = 0.026)
Postoperative Benefits:
- Faster lactate normalization (6 vs 13 hours, P = 0.04) 1
- Earlier tolerance to enteral feeding 1
- Reduced platelet concentrate and epinephrine requirements in high MELD patients 3
- Prevention of small-for-size syndrome in grafts >0.6% GRWR 2
Shunt Management Strategy
Self-Regulating Closure:
Use ligamentum teres hepatis interposition to create a shape-memory graft that spontaneously constricts as the graft regenerates, avoiding both premature closure (causing portal hypertension) and prolonged patency (causing graft atrophy) 8.
Expected Patency:
- 80% at 1 month
- 55% at 3 months
- 26% at 6 months
- 20% at 1 year 2
Shunts with lower post-creation portal pressure close faster than those with higher pressure 8.
Critical Technical Considerations
Avoid Common Pitfalls:
- Don't create TPCS routinely in all LDLT cases—reserve for high-risk situations or elevated portal pressure 3
- Measure portal pressure intraoperatively before deciding on shunt creation 2
- In obese patients or hypertrophic segment I, use iliac venous conduit interposition rather than struggling with direct anastomosis 4
- Position shunt to avoid compromising future retransplantation if needed 9
Graft Regeneration:
With TPCS, graft volume reaches:
- 84.3% of standard liver volume in right lobe grafts
- 95.4% in left lobe grafts at 3 months post-transplant 2
Safety Profile
TPCS is safe with no increase in major morbidity, 90-day mortality, or ICU/hospital stay compared to no-shunt technique 1. The technique is particularly beneficial in high-risk patients where it equalizes outcomes to standard-risk cases despite more complicated operative conditions 3.
The decision should be based on measured intraoperative portal pressure and anticipated surgical difficulty, not surgeon preference alone 7.